ライフサイエンスコーパス: toxicity

1 py until disease progression or unacceptable toxicity).

2 are unlikely to cause serious cardiovascular toxicity.

3 ge scenarios somewhat attenuated nanoplastic toxicity.

4 repair upon FECH inhibition, without ocular toxicity.

5 hich, although effective, cause considerable toxicity.

6 oxychloroquine toxicity, and 25 with quinine toxicity.

7 tients, whereas all are exposed to potential toxicity.

8 g motifs (UIMs) that enhance aggregation and toxicity.

9 a possible link to aggregation pathways and toxicity.

10 or until disease recurrence or unacceptable toxicity.

11 ation, structure, aggregation, clearance and toxicity.

12 to serve as a proxy for examining potential toxicity.

13 take, intracellular trafficking, potency and toxicity.

14 and amines, which could have a high LOD and toxicity.

15 options, RPT has shown efficacy with minimal toxicity.

16 y their on-target and dose-limiting platelet toxicity.

17 atment, but is often discontinued because of toxicity.

18 greatly induced their expression under Buta toxicity.

19 18, and 75 patients were fully evaluable for toxicity.

20 lesions, but are associated with significant toxicity.

21 offers superior tolerability for hematologic toxicity.

22 ps identified as being vulnerable to greater toxicity.

23 tly than single treatments in the absence of toxicity.

24 rate at the price of a moderate increase in toxicity.

25 nt on tenofovir-based ART with mitochondrial toxicity.

26 xcluded degradates with likely overestimated toxicity.

27 Four patients (6%) died as a result of toxicity.

28 th untreated controls, because of whole-body toxicity.

29 s) until disease progression or unacceptable toxicity.

30 mulation of cholesterol crystals or signs of toxicity.

31 ogical conditions associated with delayed OP toxicity.

32 ects against tenofovir-induced mitochondrial toxicity.

33 ng S1R confers neuroprotection against TDP43 toxicity.

34 , oxidative stress, and Abeta 1-42 oligomers toxicity.

35 uent monitoring of sodium levels could avoid toxicity.

36 crystallizes in vivo and of its mechanism of toxicity.

37 t this effect was not accompanied by general toxicity.

38 gastrointestinal, renal, and cardiovascular toxicity.

39 did not always correlate with an increase in toxicity.

40 e association between the infarcts and Abeta toxicity.

41 rove clinical outcome and reduce the risk of toxicity.

42 ever, their use can be accompanied by severe toxicity.

43 rincipled drug combinations tend to have low toxicity.

44 oplasmic TDP-43, TDP-43 aggregation and cell toxicity.

45 NCTN) study to improve outcomes and decrease toxicity.

46 ly until disease progression or unacceptable toxicity.

47 tibodies are critical for their efficacy and toxicity.

48 nistration, raising concerns about long term toxicity.

49 a neuroblastoma xenograft model with minimal toxicity.

50 (7) CART-19 at inducing CR without excessive toxicity.

51 ntreated controls and resulted in whole-body toxicity.

52 ure development of radiation-induced retinal toxicity.

53 or considering a patient's risk of financial toxicity.

54 r, but is limited by short exposure and high toxicities.

55 ed triptolide-associated hepatic and cardiac toxicities.

56 generally well tolerated without unexpected toxicities.

57 rapy-resistant disease and treatment-related toxicities.

58 nhibition capability without severe systemic toxicities.

59 significant proportion develop inflammatory toxicities.

60 There were no treatment-related grade 4-5 toxicities.

61 y improving efficacy while reducing systemic toxicities.

62 n.RESULTSEBV-CTLs did not induce significant toxicities.

63 tained high local dose with reduced systemic toxicities.

64 I-omburtamab was well tolerated with minimal toxicities.

65 and off can reduce cumulative dose and limit toxicities.

66 grade >= 3 GI (2.5% v 3.9%) or genitourinary toxicity (2.9% v 2.9%).

67 EK inhibitors are limited owing to on-target toxicities(5-7) and drug resistance(8-10).

68 , distribution, metabolism, elimination, and toxicity (ADMET) properties of drug candidates are impor

69 Selenium (Se) deficiency and toxicity affect over a billion people worldwide.

70 cts contributes to variation in efficacy and toxicity after axi-cel therapy in LBCL, and that day 7 m

71 rmed, examining the biochemical and clinical toxicity after PRRT when using a fast-infusion protocol

72 rulence-associated CdiA-CT domain to promote toxicity against mammalian cells in culture and lethalit

73 ensive treatments that result in significant toxicities and adverse effects.

74 different strains of amyloids with distinct toxicities and pathology-spreading properties.

75 utcomes and report on unique CD22 CAR T-cell toxicities and toxicity mitigation strategies.

76 dditional therapies to offset the associated toxicities and/or costs.

77 e was a statistical correlation between lead toxicity and abdominal pain consistency and intensity, c

78 Toxicity and biodistribution assessments on repeat dosin

79 ls, increased GA turnover, and decreased RAN toxicity and co-aggregation of proteasome and autophagy

80 R is the most important type due to its high toxicity and common detection in the environment.

81 Acute and late treatment-related toxicity and cosmesis outcomes were significantly in fav

82 lenge for water purification due to its high toxicity and difficulty to remove at ultra-dilute concen

83 dual variability in metabolism and resulting toxicity and effectiveness of drugs used for tuberculosi

84 nucleotides to the host, and exacerbates DNA toxicity and host death without mitochondrial RNA or DNA

85 very have been related to problems regarding toxicity and immunogenicity, escalating the need for an

86 Chemotherapy causes off-target toxicity and is often ineffective against solid tumors.

87 vivo experiments, we further analyze Abeta42 toxicity and its suppression by PI3K activation in in vi

88 s a determining factor for its environmental toxicity and mobility.

89 e therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles.

90 ons, CGG RAN-blocking ASOs suppressed repeat toxicity and prolonged survival.

91 olytic drugs do not carry significant ocular toxicity and provide further support for additional eval

92 vity predisposes HPV+ HNSCC to WEE1i-induced toxicity and provide mechanistic insights into WEE1i and

93 peptides in modulating Abeta aggregation and toxicity and provide new insight into the potential path

94 ts associated with their use, including drug toxicity and resistance.

95 ing of Bti efficacy and the path to improved toxicity and spectrum has been ignorance of how Cyt1Aa c

96 to treat visceral leishmaniasis suffer from toxicity and the emergence of parasite resistance, and s

97 en implicated in neurodegeneration, cellular toxicity and the propagation, which accompanies disease

98 ion metabolites in predicting 5-fluorouracil toxicity and the role of the agmatine pathway metabolite

99 nsors to therapeutic treatment agents, their toxicity and their utility in chemical sensing.

100 nds are not highly selective and can exhibit toxicity and/or potential off-target effects.

101 tion of abiotic (nutrient deprivation, metal toxicity) and biotic (pathogens, herbivores) stress fact

102 oquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicity.

103 efficiency by approximately twofold, reduces toxicity, and enables lyophilized storage without loss o

104 ome success, there are underlying targeting, toxicity, and immunogenicity challenges.

105 r earlier report of high response rates, low toxicity, and improved quality of life with (177)Lu-PSMA

106 s of people are impacted by Se deficiency or toxicity, and in geologic history, several mass extincti

107 ts included progression-free survival (PFS), toxicity, and quality of life (QOL).

108 -pocket costs that predict risk of financial toxicity are difficult to identify.

109 lapping mechanism between ischemia and Abeta toxicity are lacking.

110 were demonstrated almost identical in vitro toxicity as unmodified chitin and chitosan.

111 DHD medications and potential cardiovascular toxicity as well as nondrug strategies for managing ADHD

112 Moreover, toxicity assays with these variants revealed that Cyt1Aa

113 To support rapid chemical toxicity assessment and mechanistic hypothesis generatio

114 ls that demonstrate therapeutic efficacy and toxicities associated with each class of drug.

115 could explain the lower level of neurologic toxicity associated with Hu19-CD828Z.

116 ndpoints were determination of dose-limiting toxicities at the maximum administered dose, safety and

117 Subacute toxicity at 8 wk and chronic toxicity at 1 y after administration were evaluated for

118 Subacute toxicity at 8 wk and chronic toxicity at 1 y after admin

119 ular drug retention and did not cause ocular toxicity at a dose of 150 mug of active agent.

120 thermal stability, biodegradability, and low toxicity, being a candidate for the control of phytopath

121 Avadomide plus obinutuzumab has a manageable toxicity, being a tolerable treatment option for most pa

122 Toxicity between treatment and 3 mo was evaluated accord

123 ents of sediment in Flanders to results from toxicity bioassays performed on the ostracod Heterocypri

124 alcohols for their natural availability, low toxicity, biodegradability, diversity, high abundance, a

125 ta, alters its aggregation, and inhibits its toxicity both in vitro and in vivo In this study, we inv

126 Alzheimer's disease and is assumed to cause toxicity by its interaction with the neuron membrane.

127 t with models in which prion propagation and toxicity can be mechanistically uncoupled.

128 llular role of PrimPol is protecting against toxicity caused by ART and individuals with inactivating

129 ty control (RQC) pathways protect cells from toxicity caused by incomplete protein products resulting

130 the potential for increased mobilization and toxicity caused by the reduction of arsenate [As(V)] to

131 RDV in patients with SRI due to theoretical toxicity concerns.

132 d using the National Cancer Institute Common Toxicity Criteria scale.

133 ts included feasibility, metabolic response, toxicity (CTCAE), local progression-free survival (LPFS)

134 eatures should be considered in interpreting toxicity data and the development of ecological risk ass

135 Limited toxicity data on electronic cigarette (ECIG) impede evid

136 o extrapolate chronic information from acute toxicity data.

137 treated at 1 mg/kg experienced dose-limiting toxicity (DLT) from immune-related adverse events (irAEs

138 Safety, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), and pre

139 s therapy spares steroid exposure and allied toxicity, does not compromise long-term survival outcome

140 the entire Distributed Structure-Searchable Toxicity (DSSTox) Database (~800,000 chemicals).

141 When these mechanisms fail, toxicity due to the nutrient surplus ensues, leading to

142 Chronic toxicity evaluations of nanotechnology-based drugs are e

143 Whereas direct toxicity exerted by APAP metabolites is a key determinan

144 Nevertheless, acute toxicity experiments with (212)Pb-anti-mCD38 established

145 All toxicity features, however, are suppressed by the coexpr

146 supplement was found to reduce severe acute toxicities for head and neck squamous cell cancer (HNSCC

147 during HD is a potential treatment for drug toxicities for which current recommendations exclude HD

148 biological systems is regulated to minimize toxicity for biological function.

149 erapy protocols, within admissible limits of toxicity, for palliative treatment of metastatic NSCLC.

150 Toxicities from targeted therapies are usually secondary

151 f opioid use disorders (OUDs) and to prevent toxicity from accidental and deliberate exposure to fent

152 proteasome inhibition and reduce the risk of toxicity from long-term treatment.

153 bility caused by its hydrophilic nature, low-toxicity, good environmental stability, and nanostructur

154 Because potential fibril toxicity has to be mediated by interactions of the fibri

155 These PROTACs can cause on-target toxicities if the POIs are not tumor-specific.

156 t to an amount that would cause any systemic toxicity if taken at the recommended dosages.

157 n anti-CD19 CAR T cell efficacy and HLH-like toxicities in a syngeneic murine model.

158 ong-term consumption of RCO produces various toxicities in mice with important implications for human

159 nd does not cause severe on-target/off-tumor toxicity in a human CD147 transgenic mouse model.

160 ing Abeta peptide on-pathway aggregation and toxicity in a human neuroblastoma SH-SY5Y cell line.

161 vents age-dependent alphaSyn aggregation and toxicity in C. elegans models and prevents alphaSyn-medi

162 so induce different amounts of pathology and toxicity in cells and in mice, suggesting that the struc

163 estigated the effects of annexin A5 on Abeta toxicity in choroid plexus.

164 benefits of Se: (1) dietary Se reduces MeHg toxicity in consumers; (2) environmental Se reduces Hg b

165 Here, we observed toxicity in early Xenopus laevis embryos when using such

166 oth of which contribute to treatment induced toxicity in immunocompetent mice.

167 of the HepaRG cell line to study ddC-induced toxicity in isogenic proliferating (undifferentiated) an

168 t hepatotropism or induce liver inflammatory toxicity in mice, demonstrating the exceptional safety p

169 underlying mechanism by which ethanol causes toxicity in muscle is poorly understood.

170 y, good biocompatibility, and low biological toxicity in normal physiological environments.

171 Recent reports of tenofovir toxicity in patients taking ART for HIV cannot be explai

172 ificantly prolonged PFS and OS but increased toxicity in patients with NSCLC.

173 e attention due to their high reactivity and toxicity in vitro and in vivo.

174 ossible role of PrimPol in tenofovir-induced toxicity in vitro and show that tenofovir-diphosphate in

175 ifically antagonized TDP-43 condensation and toxicity in yeast and TDP-43 aggregation in human cells.

176 composition of a legacy AFFF sample and its toxicity in zebrafish embryos.

177 body distribution without increasing uptake (toxicity) in healthy tissue when co-administered with th

178 s that are required for SPB localization and toxicity include its Spc42-, Spc29-, and Cmd1-binding si

179 tcomes and a wide array of treatment-related toxicities, including those that are cardiovascular in n

180 Two patients experienced severe retinal toxicity, including 1 with severe vision loss.

181 ction, and their use can cause mitochondrial toxicity, including mitochondrial DNA (mtDNA) depletion

182 rides have been made to ameliorate the acute toxicities induced by chemotherapy, long-term comorbidit

183 suggest that Si-governed mitigation of Buta toxicity is linked with favorable modifications in energ

184 The mechanism of delayed OP toxicity is thought to involve off-target inhibition of

185 To address the toxicity issue, intense recent research effort has been

186 injection of low drug doses and eliminating toxicity issues associated with multiple high dose injec

187 y of Dox and Val via ISFI can avoid systemic toxicity issues seen with clinical Pgp inhibitors.

188 the possibility of its applications without toxicity issues.

189 Since C3G has no or very low toxicity, it could be potentially used for colon cancer

190 asibility as well as heightened inflammatory toxicities, leading to dose de-escalation.

191 However, normal tissue toxicity limits the radiation dose and the curative pote

192 15) until disease progression, unacceptable toxicity, loss to follow-up, or withdrawal of consent.

193 a sustained therapeutic efficacy and reduced toxicities, macromolecular GC prodrugs have been develop

194 ds have been associated to acute and chronic toxicity, mainly in the liver.

195 herapies are usually secondary to "on target toxicities." Management is largely supportive and may in

196 Financial toxicity manifested via medical bills, changes in insura

197 ort on unique CD22 CAR T-cell toxicities and toxicity mitigation strategies.

198 d gene expression studies in rat disease and toxicity models.

199 s, but its limited availability and inherent toxicity necessitate the strict regulation of iron homeo

200 No grade 3/4 renal toxicity occurred.

201 the maximum tolerated dose and dose limiting toxicities of brentuximab vedotin combined with ipilimum

202 off-target effects, immune stimulation, and toxicities of metabolites of these therapeutic agents.

203 rgely from uncertainties about the long-term toxicities of such complexes, due in part to the speciat

204 R) modulates the deposition, processing, and toxicity of Abeta (Abeta) peptides.

205 The toxicity of baboon oligomers and lack of significantly d

206 eripheral neuropathy, the main dose-limiting toxicity of bortezomib.

207 nausea and vomiting (CINV) is a significant toxicity of chemotherapy.

208 The system exploits the toxicity of commonly used broad-spectrum antibiotics gen

209 Toxicity of ipilimumab and nivolumab was also assessed.

210 The toxicity of iron stems from its potential to catalyze fo

211 al analysis of urine and plasma confirmed no toxicity of LNCs compared to control.

212 passed the QC checkpoint by the PheRS, this toxicity of m-Tyr may result from interfering with amino

213 aB kinase epsilon (IKKepsilon), enhanced the toxicity of mutant CHMP2B in the fly eye and that Ik2 ov

214 In addition, systemic toxicity of NAMPT inhibition remains a significant conce

215 d evaluating the potential allergenicity and toxicity of newly-expressed proteins.

216 Herein, we investigated one-year toxicity of non-surface modified silica nanoparticles (S

217 a protective effect of TTR against cellular toxicity of pathogenic Abeta, a protein associated with

218 The amounts and toxicity of reagents, generated waste, energy requiremen

219 e rate and longer, albeit limited, PFS, with toxicity of the combination regimen comparable to prior

220 tated drawing conclusions about the relative toxicity of the exposures within each case study.

221 orphological changes, however, decreased the toxicity of the H(2)O(2)/gluconic acid.

222 The reasons for this are the toxicity of the heme and the fact that it acts as a hemo

223 However, TAI fell out of favor due to high toxicity of the intestine.

224 dy is critically important to understand the toxicity of these protein species.

225 The physical, chemical, and toxicity of treated mesquite flour were also investigate

226 ) have been raised, experimentally assessing toxicity of various ENMs is challenging and time-consumi

227 ne reactions can help to protect against the toxicity of venoms.

228 ysis of beta-phenylethylamine and tryptamine toxicity on a human intestinal epithelial cell line.

229 No signs of toxicity on biochemical, hematological parameters.

230 m 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 w

231 ain path and then dropped down due to either toxicity or the emergence of resistance.

232 ab until disease progression or unacceptable toxicity or to stop nivolumab with the option of on-stud

233 roids, until treatment failure, unacceptable toxicity, or death.

234 ycle until disease progression, unacceptable toxicity, or patient withdrawal.

235 Toxicity over Time analyses provided clinically relevant

236 wide level, which highlights their different toxicity pathways despite their similar structures.

237 ation of Pif1 exacerbated its overexpression toxicity phenotype, which was alleviated upon deletion o

238 We aimed to group PFAS based on shared toxicity phenotypes.

239 the resulting CAG threshold length-triggered toxicity process.

240 ating improved efficacy and a more favorable toxicity profile are poised to alter the landscape of RE

241 e biomarkers, demonstrating a more favorable toxicity profile in vivo.

242 apy to further improve clinical response and toxicity profiles has grown.

243 d compounds has highlighted new SAR, and low toxicity profiles of pyroglutamides herein described are

244 1 inhibition cannot be deconvoluted from the toxicity profiles of the available multikinase inhibitor

245 Gene toxicity provides potential insights into function, and

246 Supplementation was not associated with toxicity, relapse, or survival.

247 ntified the group at greatest risk for early toxicity-related death or treatment failure.

248 loratory analysis, the nontumoral liver dose-toxicity relationship was also evaluated.

249 Late-onset inflammatory toxicities resembling hemophagocytic lymphohistiocytosis

250 difficult to accurately evaluate associated toxicity responses representative of real-world exposure

251 More frequent hematologic toxicity resulted in more reduced dosing/treatment disco

252 specific microhabitat preferences can affect toxicity risks.

253 ns; acute graft-versus-host disease; Bearman toxicity score; sinusoidal obstruction syndrome; serious

254 These effects occur without toxicity, showing the potential of these combined therap

255 oping zebrafish embryos over seven days with toxicity similar to injected RNA and strongly improved s

256 Toxicity studies in rats and human dosimetry estimates s

257 Activity-escalated acute and chronic toxicity studies of (225)Ac-L1 revealed off-target radio

258 Ocular toxicity studies revealed that intravitreal injection of

259 angiocyte channel, allowing proof-of-concept toxicity studies with the biliary toxin, biliatresone, a

260 Additionally, the in vitro host toxicity study also confirmed that the DCP4 up to 5,000

261 Further, in acute toxicity study, single dose (50, 300, 1000 and 2000 mg/k

262 gious apprehensions, financial gain and food-toxicities such as meat allergies.

263 Conventional toxicity tables that include the incidence of high-grade

264 due to convergent adaptations in the primary toxicity target and a major detoxification enzyme.

265 s of biofabrication method), performing drug toxicity-testing, and testing pharmaceutical efficacy/sa

266 pport equivalent safety to placebo with less toxicity than oral iron.

267 OH-metabolites, which often display a higher toxicity than their parental compounds.

268 e rate, worse survival outcomes, and greater toxicity than younger patients.

269 lect the continuous, lower grade symptomatic toxicities that are particularly relevant to treatment t

270 CRS) is a life-threatening treatment-related toxicity that limits the full therapeutic potential in a

271 mmune-related adverse events (irAEs), immune toxicities thought to be autoimmune in origin.

272 (HSA), inhibits alphaS oligomer (alphaS(n)) toxicity through a three-pronged mechanism.

273 strategies to alleviate radiotherapy-induced toxicity to healthy tissues.

274 resulting in high tumor cell killing and low toxicity to surrounding tissues.

275 were first calculated by assuming equimolar toxicity to the most toxic parent; final analysis exclud

276 The compounds presented mild toxicity toward mammalian cell lines.

277 includes proapoptotic genes and potentiates toxicity triggered by tumor necrosis factor alpha (TNF-a

278 e mechanism by which ALK overactivity drives toxicity upon TKI withdrawal remained obscure.

279 le treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable dosing optio

280 with different modes of action (i.e. CdCl(2) toxicity versus ion pump inhibition by ouabain), a signi

281 y, the model was extended to reflect mixture toxicity via concentration addition.

282 Incidence of grade >= 3 late RT-related toxicities was compared by log-rank test.

283 AFFF toxicity was assessed in zebrafish embryos in comparison

284 Neurologic toxicity was evaluated during an 8-month surveillance: n

285 hese nanoparticles on cell proliferation and toxicity was evaluated, which clearly showed a synergic

286 No dose-related toxicity was found with cooling anesthesia.

287 Dose-limiting toxicity was not observed.

288 e of higher trophic level bioaccumulation or toxicity was observed when L. vannamei (Pacific whiteleg

289 Toxicity was predominantly low grade.

290 mplication of cytoplasmic transport in d-Ser toxicity was unsurprising, disruption of a single transp

291 e CR and determine why CR deletion generates toxicity, we designed PrP(C) constructs wherein either t

292 CAR-NKT cell infusion, and no dose-limiting toxicities were observed.

293 Post-Y90 toxicities were recorded.

294 No dose-limiting toxicities were reported.

295 Several asparaginase-associated toxicities were studied.

296 Deaths due to study drug toxicity were reported in two (1%) patients in the durva

297 units in the brain after ischemia and Abeta toxicity will help in the design of effective and altern

298 igomers and lack of significantly detectable toxicity with exogenously added amyloid fibers is consis

299 is widely used in patients with paracetamol toxicity with limited evidence of benefit in liver injur

300 Whether this efficacy, and the rates of toxicity, would be consistent in a postcommercial settin